Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.

NCT03286842 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03286842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03286842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
January 17, 2018
Completion date
October 8, 2021
Enrollment
256 (actual)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

germline brca1/2 mutations, her2-ve metastatic breast cancer, somatic brca1/2 mutations